Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates a

--Intravesical enfortumab vedotin demonstrated antitumor activity and limited systemic exposure in preclinical models of non-muscle invasive bladder cancer----Antibody specificity, antitumor activity and safety profile of SGN-ALPV in preclinical models provide basis for the first-in-human phase 1 clinical study--BOT...

Related Keywords

California ,United States ,Washington ,Canada ,Switzerland ,Seattle ,American ,David Caouette ,Peggy Pinkston ,Scott Peterson ,Enfortumab Vedotin ,Astellas Pharma Us Inc ,Research At Seagen ,Nasdaq ,Seagen Inc ,Exchange Commission ,Astellas Pharma Inc ,American Association For Cancer Research ,European Union ,Corporate Communications ,American Association ,Cancer Research ,Annual Meeting ,New Orleans ,Astellas Pharma ,Senior Vice President ,Seagen Programs Presented ,Seagen Presentations ,Clinical Pharmacology ,Immune Mechanisms Invoked ,Drug Conjugates ,Annual Report ,Vedotin Antibody Drug Conjugate Targeting ,Highly Potent Therapeutic Agent ,Multiple Preclinical Cancer ,Vice President ,Investor Relations ,